Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Cady

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Headache|September 12, 2013
Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/NapRoger Cady, Robert Nett, Kent Dexter, et al.
Headache|May 20, 2021
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcomeRichard B Lipton, David W Dodick, Jessica Ailani, et al.
Headache|April 1, 2010
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrheaPaul L Durham, Carrie V Vause, Frederick Derosier, et al.
Headache|November 23, 2011
Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover studyFrederick Derosier, Fred Sheftell, Stephen Silberstein, et al.
Headache|August 31, 2020
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic MigraineCarrie R Houts, R J Wirth, James S McGinley, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 20, 2020
Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 studyCarrie R Houts, James S McGinley, R J Wirth, et al.
Journal of Neurology|December 12, 2024
Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measuresStewart J Tepper, Merle L Diamond, Joe Hirman, et al.
Clinical Therapeutics|June 6, 2006
A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adultsJeanette Wendt, Roger Cady, Richard Singer, et al.
The Journal of Headache and Pain|November 26, 2021
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studiesTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
Frontiers in Immunology|November 11, 2021
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of MigraineSusan Pederson, David M Biondi, Brent Allan, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Headache|September 12, 2013
Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/NapRoger Cady, Robert Nett, Kent Dexter, et al.
Headache|May 20, 2021
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcomeRichard B Lipton, David W Dodick, Jessica Ailani, et al.
Headache|April 1, 2010
Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrheaPaul L Durham, Carrie V Vause, Frederick Derosier, et al.
Headache|November 23, 2011
Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover studyFrederick Derosier, Fred Sheftell, Stephen Silberstein, et al.
Headache|August 31, 2020
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic MigraineCarrie R Houts, R J Wirth, James S McGinley, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 20, 2020
Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 studyCarrie R Houts, James S McGinley, R J Wirth, et al.
Journal of Neurology|December 12, 2024
Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measuresStewart J Tepper, Merle L Diamond, Joe Hirman, et al.
Clinical Therapeutics|June 6, 2006
A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adultsJeanette Wendt, Roger Cady, Richard Singer, et al.
The Journal of Headache and Pain|November 26, 2021
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studiesTimothy R Smith, Egilius L H Spierings, Roger Cady, et al.
Frontiers in Immunology|November 11, 2021
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of MigraineSusan Pederson, David M Biondi, Brent Allan, et al.
Pageof 10